Asthma is recognised to arise from complex interactions between environmental exposure
and disease-susceptibility genetic contributions. 1 Pharmacological management of the …

Asthma is a chronic disorder causing inflammation and reversible airway obstruction that
affects approximately 300 million individuals worldwide. The incidence of asthma has nearly …

The study of pharmacogenetics has expanded from what were initially casual drug response
observations present in families, to a fully-fledged science with direct therapeutic …

Asthma affects an estimated 300 million individuals worldwide, resulting in substantial
morbidity, mortality, and health care utilization. The response to the three major classes of …

A patient's response to asthma therapy is determined by both genetic and environmental
factors. In the past 10 years, we have witnessed significant progress in the field of asthma …

Current asthma treatments are effective for most but not all patients. Asthma is classified as a
complex genetic disease with its pathogenesis and expression (severity) determined by the …

Pharmacogenetic approaches provide the opportunity to improve prescribing for asthmatic
patients in order to optimise efficacy and prevent side-effects. Currently, there are …

There is increasing evidence associating differences in drug response to genetic variants.
Pharmacogenetics is the rapidly evolving discipline that identifies these genetic variants to …

An individual's response to anti‐asthma medication is likely to arise from a complex
interaction between social, environmental and inherited factors. Studies indicate that genetic …

Asthma is a common chronic disease of unknown cause, for which a number of
pharmacological treatments have been developed. These treatments have a modest efficacy …